Pierre Chancel - Sanofi Sr Marketing
| SNYN Stock | MXN 958.00 6.00 0.62% |
Executive
Pierre Chancel is Sr Marketing of Sanofi
| Age | 66 |
| Phone | 33 1 53 77 40 00 |
| Web | https://www.sanofi.com |
Sanofi Management Efficiency
The company has return on total asset (ROA) of 0.0607 % which means that it generated a profit of $0.0607 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0959 %, meaning that it generated $0.0959 on every $100 dollars invested by stockholders. Sanofi's management efficiency ratios could be used to measure how well Sanofi manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 4 records | EXECUTIVE Age | ||
| Johanna Mercier | Gilead Sciences | 53 | |
| Jennifer Zachary | Merck Company | 45 | |
| Arvind Sood | Amgen Inc | N/A | |
| Cristina Wilbur | Roche Holding AG | 56 | |
Management Performance
| Return On Equity | 0.0959 | |||
| Return On Asset | 0.0607 |
Sanofi Leadership Team
Elected by the shareholders, the Sanofi's board of directors comprises two types of representatives: Sanofi inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sanofi. The board's role is to monitor Sanofi's management team and ensure that shareholders' interests are well served. Sanofi's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sanofi's outside directors are responsible for providing unbiased perspectives on the board's policies.
| JeanBaptiste Chatillon, CFO, Executive Vice President Member of the Executive Committee | ||
| Roy Papatheodorou, Gen VP | ||
| Josephine Fubara, Chief Care | ||
| Paul Hudson, CEO Director | ||
| Pierre Chancel, Sr Marketing | ||
| Bruno Mnard, Chief officer | ||
| Laurent Gilhodes, Principal Accounting | ||
| Dante Beccaria, Global VP | ||
| Eva SchaeferJansen, Head Relations | ||
| Josep Catlla, Head Communications |
Sanofi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sanofi a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0959 | |||
| Return On Asset | 0.0607 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 2.69 T | |||
| Shares Outstanding | 2.47 B | |||
| Shares Owned By Institutions | 10.26 % | |||
| Price To Earning | 414.95 X | |||
| Price To Book | 1.61 X | |||
| Price To Sales | 52.71 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Sanofi Stock Analysis
When running Sanofi's price analysis, check to measure Sanofi's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi is operating at the current time. Most of Sanofi's value examination focuses on studying past and present price action to predict the probability of Sanofi's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi's price. Additionally, you may evaluate how the addition of Sanofi to your portfolios can decrease your overall portfolio volatility.